靶向白细胞介素 4 受体 α：治疗皮肤自身免疫性大疱性疾病的新方法？
Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
机构信息
Di.S.SAL Section of Dermatology, University of Genoa, Via Pastore 1, Genoa, Italy.
Section of Dermatology, IRCCS San Martino Policlinic Hospital, Genoa, Italy.
出版信息
Dermatol Ther. 2020 Jan;33(1):e13190. doi: 10.1111/dth.13190. Epub 2020 Jan 2.
Bullous pemphigoid, mucous membrane pemphigoid, and pemphigus vulgaris are different cutaneous autoimmune blistering diseases, with complex pathogenic mechanisms. In all of them, a type-2 response is thought to have a central role. Interleukin 4 and Interleukin 13 are crucial cytokines in type-2 response. Treatment of these conditions is often challenging. Dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin-4 receptor IL-4Rα, has the potential to inhibit both IL-4 and IL-13. We propose IL-4Rα as a theoretical drug target for cutaneous autoimmune bullous diseases.
大疱性类天疱疮、黏膜类天疱疮和寻常型天疱疮是三种不同的皮肤自身免疫性水疱病，具有复杂的发病机制。在所有这些疾病中，都认为 2 型反应起着核心作用。白细胞介素 4 和白细胞介素 13 是 2 型反应中的关键细胞因子。这些疾病的治疗往往具有挑战性。度普利尤单抗是一种重组的全人源 IgG4 单克隆抗体，对人白细胞介素-4 受体（IL-4Rα）具有特异性结合能力，具有抑制白细胞介素 4 和白细胞介素 13 的潜力。我们提出 IL-4Rα 作为皮肤自身免疫性大疱性疾病的理论药物靶点。
Zotero 插件